39.55 USD
-0.17 (-0.43%)
39.55 USD
0 (0%)
Overall RPRX gets a fundamental rating of 6 out of 10. We evaluated RPRX against 190 industry peers in the Pharmaceuticals industry. While RPRX has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on RPRX.
1. Profitability
1.1 Basic Checks
- In the past year RPRX was profitable.
- RPRX had a positive operating cash flow in the past year.
- RPRX had positive earnings in each of the past 5 years.
- RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 3.95%, RPRX belongs to the top of the industry, outperforming 84.74% of the companies in the same industry.
- The Return On Equity of RPRX (11.93%) is better than 86.32% of its industry peers.
- The Return On Invested Capital of RPRX (6.43%) is better than 84.21% of its industry peers.
- RPRX had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 12.84%.
- The last Return On Invested Capital (6.43%) for RPRX is above the 3 year average (5.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
- Looking at the Profit Margin, with a value of 32.55%, RPRX belongs to the top of the industry, outperforming 95.26% of the companies in the same industry.
- RPRX's Profit Margin has declined in the last couple of years.
- Looking at the Operating Margin, with a value of 65.22%, RPRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- RPRX's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RPRX is destroying value.
- Compared to 1 year ago, RPRX has less shares outstanding
- Compared to 5 years ago, RPRX has more shares outstanding
- RPRX has a worse debt/assets ratio than last year.
2.2 Solvency
- RPRX has an Altman-Z score of 1.70. This is a bad value and indicates that RPRX is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.70, RPRX is in line with its industry, outperforming 56.84% of the companies in the same industry.
- RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
- RPRX has a better Debt to FCF ratio (9.47) than 79.47% of its industry peers.
- RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of RPRX (1.34) is worse than 76.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.7 |
ROIC/WACC0.75
WACC8.56%
2.3 Liquidity
- RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- RPRX's Current ratio of 3.48 is in line compared to the rest of the industry. RPRX outperforms 55.26% of its industry peers.
- RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- RPRX's Quick ratio of 3.48 is in line compared to the rest of the industry. RPRX outperforms 57.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 0.24% over the past year.
- The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
- RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
- Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 4.52% on average per year.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
- Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.53% on average per year.
- Based on estimates for the next years, RPRX will show a quite strong growth in Revenue. The Revenue will grow by 10.65% on average per year.
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.65%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.62, the valuation of RPRX can be described as reasonable.
- Based on the Price/Earnings ratio, RPRX is valued cheaper than 91.05% of the companies in the same industry.
- RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.47.
- Based on the Price/Forward Earnings ratio of 7.64, the valuation of RPRX can be described as very cheap.
- Based on the Price/Forward Earnings ratio, RPRX is valued cheaply inside the industry as 91.58% of the companies are valued more expensively.
- RPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 7.64 |
4.2 Price Multiples
- 83.68% of the companies in the same industry are more expensive than RPRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.17 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- RPRX has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as RPRX's earnings are expected to grow with 13.48% in the coming years.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y12.38%
EPS Next 3Y13.48%
5. Dividend
5.1 Amount
- RPRX has a Yearly Dividend Yield of 2.19%. Purely for dividend investing, there may be better candidates out there.
- Compared to an average industry Dividend Yield of 0.35, RPRX pays a better dividend. On top of this RPRX pays more dividend than 94.21% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.89, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.19% |
5.2 History
- RPRX has been paying a dividend for over 5 years, so it has already some track record.
- RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
39.55
-0.17 (-0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners81.5%
Inst Owner Change0.13%
Ins Owners1.56%
Ins Owner Change7.63%
Market Cap22.83B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts84.29
Price Target46.34 (17.17%)
Short Float %7.15%
Short Ratio6.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.19% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)0.74%
PT rev (3m)4.57%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)2.06%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)4.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.2%
Revenue NY rev (1m)0.39%
Revenue NY rev (3m)1.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 7.64 | ||
| P/S | 9.72 | ||
| P/FCF | 24.17 | ||
| P/OCF | 9.49 | ||
| P/B | 3.56 | ||
| P/tB | 4.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.39%
EPS(NY)5.18
Fwd EY13.09%
FCF(TTM)1.64
FCFY4.14%
OCF(TTM)4.17
OCFY10.54%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.56
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.7 |
F-Score5
WACC8.56%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.65%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.71%
EBIT Next 3Y14.53%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.62 and the Price/Book (PB) ratio is 3.56.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.